BAY 41-2272 – 25 mg

Brand:
Cayman
CAS:
256376-24-6
Storage:
-20
UN-No:
Non-Hazardous - /

Soluble guanylate cyclase (sGC), a receptor for nitric oxide (NO), is a heterodimer consisting of alpha and beta subunits, with the beta subunit featuring a heme-nitric oxide (H-NOX) binding domain.{24381} The binding of NO to H-NOX induces sGC to generate the second messenger cGMP. BAY 41-2272 is a pyrazolopyridine compound that acts as an activator of sGC, stimulating activity to a level that would be expected to cause biologically important increases in cGMP at concentrations as low as 10-100 nM.{9717} Through this effect, it inhibits platelet aggregation (IC50 = 36 nM), induces relaxation of phenylephrine-preconstricted rabbit aorta rings (IC50 = 304 nM), and reduces proliferation in smooth muscle.{9717,24380} BAY 41-2272 is effective in vivo, as it decreases mean arterial blood pressure in hypertensive rats.{9717} Unlike another sGC activator, YC-1 (Item No. 81560), BAY 41-2772 does not inhibit phosphodiesterases.{17529}  

 

Available on backorder

SKU: 10057 - 25 mg Category:

Description

An activator of sGC, stimulating activity at concentrations as low as 10-100 nM; inhibits platelet aggregation (IC50 = 36 nM), induces relaxation of preconstricted aorta rings (IC50 = 304 nM); effective in vivo, decreasing mean arterial blood pressure in hypertensive rats


Formal name: 5-cyclopropyl-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-4-pyrimidinamine

Synonyms: 

Molecular weight: 360.4

CAS: 256376-24-6

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Activators||Research Area|Cardiovascular System|Blood|Coagulation & Hemostasis||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension||Research Area|Cardiovascular System|Vasculature|Vasodilation